STOCK TITAN
  1. Home
  2. News
  3. PODD

Insulet Corporation - PODD STOCK NEWS

Welcome to our dedicated news page for Insulet Corporation (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Insulet Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Insulet Corporation's position in the market.

News
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
Rhea-AI Summary
Insulet (NASDAQ: PODD) announced plans to release its Q1 2024 financial results on May 9, 2024. The company will host a conference call at 4:30 p.m. (Eastern Time) to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
earnings
-
News
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
Rhea-AI Summary
Insulet (NASDAQ: PODD) appoints Ana Maria Chadwick as Executive Vice President, Chief Financial Officer and Treasurer. Ms. Chadwick brings extensive experience from top-tier organizations like Pitney Bowes and GE, enhancing Insulet's leadership team and financial capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
management
-
News
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
Rhea-AI Summary
Insulet Corporation (PODD) presents positive results from the OP5-003 Trial, showcasing improved glycemic outcomes with the Omnipod 5 Automated Insulin Delivery System. The trial demonstrated a 17.5% increase in time in range, reduced HbA1c levels, and improved patient-reported outcomes for individuals with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
News
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Rhea-AI Summary
Insulet Corporation (PODD) to present new clinical evidence on Omnipod 5 Automated Insulin Delivery System at ATTD conference, showcasing positive outcomes and real-world evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences
-
News
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
Rhea-AI Summary
Insulet Corporation (PODD) reports 8th consecutive year of 20%+ revenue growth, with full year 2023 revenue reaching $1.7 billion, up 30.0% from the prior year. Omnipod revenue saw significant increases, with U.S. revenue up by 41.4% and International revenue up by 13.0%. Gross margin improved to 68.3%, operating income surged to $220.0 million, and net income reached $206.3 million. The company also delivered strong fourth quarter results, with revenue up by 37.9% to $509.8 million. Insulet highlighted key achievements, including launching Omnipod 5 integrated with Dexcom’s G7 sensor and receiving CE Mark approval for integration with Abbott’s Freestyle Libre 2 Plus sensor. The company projects revenue growth of 12% to 17% for 2024, with a focus on Omnipod and operating margin of approximately 13%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
earnings
-
News
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
Rhea-AI Summary
Insulet Corporation (PODD) to present at The Raymond James & Associates 45th Annual Institutional Investors Conference. The presentation will be on March 5, 2024, at 11:35 a.m. (Eastern Time). Investors can access the live webcast on investors.insulet.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
News
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD) has received CE mark approval for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System. The system, the first and only tubeless hybrid closed loop system to achieve CE marking, is integrated with two CGM sensor brands, Abbott FreeStyle Libre and Dexcom. The Omnipod 5 integration is expected to be available in the United Kingdom and Netherlands in the first half of 2024, with additional markets to follow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
News
Imperative Care Announces Four Senior Leadership Appointments
Rhea-AI Summary
Imperative Care, a medical technology company, announced the appointment of Chuck Alpuche as COO, Peter Griffin as SVP of Operations, Scott Elliott as CLO, and Daniel Davis as CSO. Alpuche brings 40 years of senior operational expertise and previously served as the Executive VP and COO of Insulet Corporation (NASDAQ: PODD). Griffin has over 35 years of manufacturing and product development experience, and Elliott joins with 30 years of experience as a legal advisor. Davis will oversee the growth and strategic initiatives of Imperative Care's businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
News
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
Rhea-AI Summary
Insulet Corporation (PODD) announces new appointments to its Board of Directors and the retirement of two board members. Flavia Pease and Timothy Stonesifer will join the Board, while Shacey Petrovic and Corinne Nevinny will retire at the Company's 2024 Annual Meeting. The new appointees bring extensive industry expertise and distinguished careers to support and enhance the company's commitment to excellence and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
management
News
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
Insulet Corporation (PODD) to Release Q4 and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
earnings
Stock PODD logo
Insulet Corporation

Nasdaq:PODD

PODD Rankings

#727 Ranked by Market Cap
#4625 Ranked by Stock Gains
N/A Ranked by Dividends

PODD Stock Data

12.27B
69.53M
0.31%
103.67%
4.46%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Acton

About PODD

insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down